Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes

View Full Paper

Ask AI

Bookmark

Share

Key Points

Characterize baseline phenotypic features and systemic disease burden in individuals diagnosed with fibrodysplasia ossificans progressiva.
Interventional study registered under clinical trial identifier NCT02322255.
Conducted standardized cross-sectional assessments to evaluate baseline phenotypic manifestations and functional impairments across participants.
Baseline evaluations define the anatomical distribution and clinical heterogeneity of abnormal tissue ossification.
Documented baseline phenotypes provide reference parameters to track long-term disease trajectories and functional outcomes qualitatively.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Uncovers baseline clinical phenotypes in fibrodysplasia ossificans progressiva, highlighting characteristic patterns of disease progression.

This study ( NCT02322255 ) was first posted on 23 December, 2014.

No takes yet. Share an insight, caveat, or question.

Pignolo et al. (2019) studied this question.

View Full Paper

Ask AI

Bookmark

Share